December 22, 2017 / 8:47 PM / 9 months ago

BRIEF-FDA Updates Label Of Tasigna To Reflect That Certain Patients With Type Of Leukemia May Be Eligible To Stop Treatment After Sustained Response

Dec 22 (Reuters) - U.S. FDA:

* FDA UPDATES LABEL OF NOVARTIS’ TASIGNA TO REFLECT THAT CERTAIN PATIENTS WITH TYPE OF LEUKEMIA MAY BE ELIGIBLE TO STOP TREATMENT AFTER SUSTAINED RESPONSE

* FDA SAYS UPDATED PRODUCT LABEL FOR CANCER DRUG TASIGNA TO INCLUDE INFORMATION FOR PROVIDERS ABOUT HOW TO DISCONTINUE THE DRUG IN CERTAIN PATIENTS

* FDA - FDA GRANTED THE APPROVAL OF THE TASIGNA LABEL CHANGES TO NOVARTIS PHARMACEUTICALS CORPORATION Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below